Article Information
History
- March 24, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Mohamed Zardab1,2,
- Vickna Balarajah1,2,
- Abhirup Banerjee1,2,
- Konstantinos Stasinos1,2,
- Amina Saad3,
- Ahmet Imrali3,
- Christine Hughes3,
- Rhiannon Roberts3,
- Ajith Vajrala3,
- Claude Chelala3,4,
- Hemant M Kocher1,2,3,* and
- Abu Z M Dayem Ullah3,4,*
- 1Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, UK
- 2Barts and the London HPB Centre, The Royal London Hospital, Barts Health NHS Trust, London, UK
- 3Barts Pancreas Tissue Bank, Barts Cancer Institute, Queen Mary University of London, London, UK
- 4Centre for Cancer Biomarkers and Biotherapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK
- ↵*Correspondence to:
Dr Abu Z M Dayem Ullah and Prof Hemant Kocher, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK Email: d.ullah{at}qmul.ac.uk; h.kocher{at}qmul.ac.uk, Telephone: +44-2078826364
Author Contributions MZ and DU designed the study and were responsible for undertaking and completing data processing and analysis. AS, AV, AI, RR and CH contributed to patient recruitment and data collection. AB, VB and MZ performed verification of the collected data. DU and HMK oversaw the conduct and management of the study. DU and CC performed validation of the analysis with oversight and improvement of the study. MZ wrote the first draft of the report, DU, HMK and CC made critical revisions, and other authors contributed to the improvement of the final report.
Posted March 24, 2022.
Development of a Model for Differentiating PDAC from Benign Pancreatic Conditions: A Prospective Case-control Study
